This company is no longer active
PCBK Stock Overview
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Sesen Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.25 |
| 52 Week High | US$18.19 |
| 52 Week Low | US$6.88 |
| Beta | 0.83 |
| 1 Month Change | -4.21% |
| 3 Month Change | 3.08% |
| 1 Year Change | -8.66% |
| 3 Year Change | -22.36% |
| 5 Year Change | -41.71% |
| Change since IPO | -31.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| PCBK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.6% | 0.8% | 0.7% |
| 1Y | -8.7% | -11.0% | 13.8% |
Return vs Industry: PCBK underperformed the German Biotechs industry which returned 10.9% over the past year.
Return vs Market: PCBK underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| PCBK volatility | |
|---|---|
| PCBK Average Weekly Movement | 18.9% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: PCBK's share price has been volatile over the past 3 months.
Volatility Over Time: PCBK's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 17 | Thomas Cannell | sesenbio.com |
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent.
Sesen Bio, Inc. Fundamentals Summary
| PCBK fundamental statistics | |
|---|---|
| Market cap | €2.42b |
| Earnings (TTM) | -€18.84m |
| Revenue (TTM) | €37.90m |
64.0x
P/S Ratio-128.7x
P/E RatioIs PCBK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PCBK income statement (TTM) | |
|---|---|
| Revenue | US$40.00m |
| Cost of Revenue | US$1.99m |
| Gross Profit | US$38.02m |
| Other Expenses | US$57.90m |
| Earnings | -US$19.88m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.098 |
| Gross Margin | 95.04% |
| Net Profit Margin | -49.71% |
| Debt/Equity Ratio | 0% |
How did PCBK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/08 20:10 |
| End of Day Share Price | 2023/03/07 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sesen Bio, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Newman | Canaccord Genuity |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Christopher Howerton | Jefferies LLC |